Stockscreener 앱 받기
25.45
1.35%
0.34
시간 외 거래:
25.45
전일 마감가:
$25.11
열려 있는:
$24.91
하루 거래량:
196.69K
Relative Volume:
0.63
시가총액:
$1.76B
수익:
$751.00K
순이익/손실:
$-74.57M
주가수익비율:
-23.07
EPS:
-1.1031
순현금흐름:
$-55.52M
1주 성능:
+1.84%
1개월 성능:
+3.67%
6개월 성능:
+78.47%
1년 성능:
+69.22%
1일 변동 폭
$24.75
$25.94
1주일 범위
$24.27
$28.48
52주 변동 폭
$12.56
$28.53
펄스 바이오 Stock (PLSE) Company Profile
명칭
Pulse Biosciences Inc
전화
510-906-4600
주소
3957 POINT EDEN WAY, HAYWARD, CA
Compare PLSE vs ISRG, BDX, ALC, MDLN, RMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PLSE
Pulse Biosciences Inc
|
25.45 | 1.79B | 751.00K | -74.57M | -55.52M | -1.1031 |
ISRG
Intuitive Surgical Inc
|
402.18 | 147.53B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
141.61 | 40.10B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
64.14 | 32.33B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
36.42 | 31.57B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
186.29 | 27.96B | 5.54B | 1.52B | 1.74B | 10.37 |
펄스 바이오 Stock (PLSE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-30 | 개시 | Mizuho | Outperform |
| 2025-07-07 | 개시 | Oppenheimer | Outperform |
| 2021-07-27 | 개시 | Stephens | Overweight |
| 2021-03-11 | 개시 | Maxim Group | Buy |
| 2021-01-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-05-12 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-02-14 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2019-02-25 | 개시 | H.C. Wainwright | Buy |
모두보기
펄스 바이오 주식(PLSE)의 최신 뉴스
What Could New Equity Awards Signal for Pulse Biosciences’ Ongoing Growth Efforts? - Kalkine Media
Pulse Biosciences (PLSE) director awarded stock options for 44,504 shares - Stock Titan
What Do Pulse Biosciences’ New Equity Awards Reveal About Executive Compensation Trends? - Kalkine Media
Director at Pulse Biosciences (NASDAQ: PLSE) receives new stock option grants - Stock Titan
Pulse Biosciences (PLSE) director receives grant of 30,000 stock options - Stock Titan
Pulse Biosciences Plunges Over 9% as Selling Pressure Intensifies, Key Support in PlayHigh Low Breadth - newsline.com
Pulse Bio to redeem remaining common stock warrants - MSN
Pulse Biosciences Shareholders Approve Board and Auditor Slate - TipRanks
Pulse Biosciences (PLSE) investors back all directors and Deloitte as 2026 auditor - Stock Titan
Pulse Biosciences (PLSE) Hovers Near Resistance After Modest GainVolume Breadth - newsline.com
Pulse Biosciences Stock (US73242P1030): Shares in focus after recent conference appearance - AD HOC NEWS
Pulse Biosciences (PLSE) upgraded to buy: What does it mean for the stock? - MSN
Pulse Biosciences Inc Annual Shareholders Meeting Transcript - GuruFocus
Pulse Biosciences (PLSE) Surges 7.6% on Increased Volume, Testing Key ResistanceSynthetic Short - newsline.com
PLSE: Directors and auditor ratified as company advances AFib trial and strengthens leadership - TradingView
Pulse Biosciences Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Pulse Biosciences (PLSE) to Redeem Outstanding Warrants by June 2026 - GuruFocus
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants - Investing News Network
Pulse Bio to redeem common stock warrants (PLSE:NASDAQ) - Seeking Alpha
Pulse Biosciences Announces Redemption of Remaining 200% Warrants - TipRanks
Pulse Biosciences to redeem remaining warrants after VWAP triggers; exercise window until July 13, 2026 - TradingView
Warrant redemption may add up to $2.1M for Pulse Biosciences (PLSE) - Stock Titan
Pulse Biosciences to redeem outstanding warrants by July 13 - Investing.com UK
Pulse Biosciences, Inc. Announces Planned Redemption Of Warrants - TradingView
Avoiding Lag: Real-Time Signals in (PLSE) Movement - Stock Traders Daily
Did New Analyst Coverage and Insider Buying Just Shift Pulse Biosciences' (PLSE) Investment Narrative? - Yahoo Finance
Assessing Pulse Biosciences (PLSE) Valuation After Strong Recent Share Price Momentum - Sahm
Does Pulse Biosciences’ (PLSE) Insider Buying Reinforce Canaccord’s Cardiac PFA Thesis or Raise New Questions? - Sahm
Pulse Biosciences board approves affiliate participation in equity sales program - Investing.com
Pulse Biosciences (PLSE) Initiated with Buy Rating and $32 Targe - GuruFocus
Canaccord initiates Pulse Biosciences stock with buy on ablation tech - Investing.com UK
Pulse Biosciences (PLSE) Surges 7.8%: Volume-Driven Breakout Tests Key ResistanceParabolic SAR - newsline.com
PLSE Initiates Coverage On by Canaccord Genuity -- Price Target Set at $32 - GuruFocus
Canaccord initiates Pulse Biosciences stock with buy on ablation tech By Investing.com - Investing.com Nigeria
Canaccord Genuity Initiates Pulse Biosciences at Buy With $32 Price Target - marketscreener.com
CCORF Initiates Pulse Biosciences(PLSE.US) With Buy Rating, Announces Target Price $32 - Moomoo
Here's why Pulse Biosciences, Inc (PLSE) is a great momentum stock to buy - MSN
PLSE Q1 2026 Earnings: Narrower-Than-Expected Loss as Pre-revenue Biotech Maintains Cost DisciplineEBITDA Estimate Trend - newsline.com
Discipline and Rules-Based Execution in PLSE Response - Stock Traders Daily
PLSE Technical Analysis & Stock Price Forecast - Intellectia AI
PLSE Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Pulse Biosciences (PLSE) Valuation Check After Strong Recent Share Price Momentum - Sahm
PLSE Q1 2026 Earnings: EPS Beat but No Revenue as Stock DeclinesEarnings Miss Alert - thelegaladvocate.com
Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026 - BioSpace
Pulse Biosciences (PLSE) Holds Steady: Key Levels in FocusButterfly Setup - The Legal Advocate
Here's Why Pulse Biosciences, Inc (PLSE) is a Great Momentum Stock to Buy - Yahoo Finance
Pulse Biosciences Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
Pulse Biosciences (PLSE) Shows Modest Gain as Stock Holds Above Key SupportPut Wall - newsline.com
Pulse Biosciences (PLSE) Rises Modestly as Shares Test Key ResistanceTICK Divergence - The Legal Advocate
Assessing Pulse Biosciences (PLSE) Valuation After Recent Share Price Surge - Sahm
Pulse Biosciences Begins nPulse Study for Malignant Thyroid Tumor Treatment - Medical Product Outsourcing
펄스 바이오 (PLSE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
펄스 바이오 주식 (PLSE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| DUGGAN ROBERT W | Director |
May 11 '26 |
Buy |
19.69 |
660,233 |
12,999,988 |
48,211,433 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Option Exercise |
1.53 |
5,000 |
7,650 |
48,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 18 '26 |
Sale |
23.64 |
5,000 |
118,200 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Option Exercise |
1.53 |
20,000 |
30,600 |
63,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 17 '26 |
Sale |
23.63 |
20,000 |
472,600 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 13 '26 |
Sale |
23.53 |
20,000 |
470,600 |
43,298 |
| Danahy Kevin Patrick | Chief Commercial Officer |
Feb 12 '26 |
Sale |
23.37 |
20,000 |
467,400 |
43,298 |
5.23%
자본화:
|
볼륨(24시간):